Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 501–600 of 1,007
Burge, R. A., & Hobbs, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.004 · Cited by 48
The Tumor Suppressor Kinase LKB1: Metabolic Nexus
Bourouh, M., & Marignani, P. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.881297 · Cited by 52
“KRAS codon 12 mutations result in amino acid substitutions of glutamine to either cysteine (G12C, 44%), valine (G12V, 23%), or aspartic acid (G12D, 17%) being the most common (Ostrem et al., 2013; Cox et al., 2014).”
BackgroundChen, L., Ning, J., Linghu, L., Tang, J. M., Liu, N., Long, Y., Sun, J., Lv, C., Shi, Y., Tao, T., et al. (2024) · Autophagy · doi:10.1080/15548627.2024.2410619 · Cited by 51
“KRAS is the one of most common carcinogenic drivers in LUAD, and KRAS mutations occur in 32% of LUADs cases [68,69].”
Gentry, L. R., Nishimura, A., Cox, A. D., Martin, T. D., Tsygankov, D., Nishida, M., Elston, T. C., & Der, C. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.656710 · Cited by 47
“Pharmacologic inhibitors of RCE1 and ICMT are being considered as anti-Ras therapeutic strategies (28).”
BackgroundSelf-citationVo, U., Vajpai, N., Flavell, L., Bobby, R., Breeze, A. L., Embrey, K. J., & Golovanov, A. P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.691238 · Cited by 40
“The P-loop (residues G10 –S17) is responsible for phosphate binding, whereas the Switch I (Y32–Y40) and Switch II (G60 –T75) regions are critical for interactions with guanine nucleotide exchange factors (7) and effector proteins (8).”
BackgroundRalB directly triggers invasion downstream Ras by mobilizing the Wave complex
Zago, G., Veith, I., Singh, M. K., Fuhrmann, L., de Beco, S., Remorino, A., Takaoka, S., Palmeri, M., Berger, F., Brandon, N., et al. (2018) · eLife · doi:10.7554/elife.40474 · Cited by 43
“Since Ras proteins are still considered undruggable (Cox et al., 2014), the focus for anti-Ras drug discovery moved downstream.”
BackgroundLakshman, B., Messing, S., Schmid, E. M., Clogston, J. D., Gillette, W. K., Esposito, D., Kessing, B., Fletcher, D. A., Nissley, D. V., McCormick, F., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005669 · Cited by 42
“The GTPase KRAS is frequently mutated in pancreatic (98%), lung (31%), and colorectal cancer (45%) (1).”
BackgroundDual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy
Xu, Y., Yu, Z., Fu, H., Guo, Y., Hu, P., & Shi, J. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c00111 · Cited by 46
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
“In LUAD, 40% of KRAS mutations are G12C, whereas KRASG12C mutations occur less frequently in COAD (7%) and PAAD (1%) [8,11,14].”
BackgroundUniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 51
“[6].”
SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status
Song, H. Y., Biancucci, M., Kang, H.-J., O'Callaghan, C., Park, S., Principe, D. R., Jiang, H., Yan, Y., Satchell, K. J. F., Raparia, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12015 · Cited by 41
“KRAS is the most frequently mutated oncogene in human cancer [23], which justifies the intensive efforts made to elucidate regulatory mechanisms, signaling transduction, feedback loops, isoform differences, and heterogeneity regarding the mutational landscape, as well as to exploit vulnerabilities in RAS-related tumor…”
BackgroundCaiola, E., Falcetta, F., Giordano, S., Marabese, M., Garassino, M. C., Broggini, M., Pastorelli, R., & Brunelli, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0954-5 · Cited by 43
Gupta, A. K., Wang, X., Pagba, C. V., Prakash, P., Sarkar‐Banerjee, S., Putkey, J. A., & Gorfe, A. A. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13519 · Cited by 44
In-silico design of peptide inhibitors of K-Ras target in cancer disease
Ghufran, M., Rehman, A. U., Shah, M., Ayaz, M., Ng, H. L., & Wadood, A. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1704880 · Cited by 43
Crystal structure of ERK2 G169D mutant
Yin, J., Jaiswal, B. S., & Wang, W. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6d5y/pdb · Cited by 42
RHOA takes the RHOad less traveled to cancer
Schaefer, A., & Der, C. J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.005 · Cited by 43
Self-citationInvestigating the NRAS 5' UTR as a Target for Small Molecules
Balaratnam, S., Torrey, Z. R., Calabrese, D. R., Banco, M. T., Yazdani, K., Xiao, L., Fullenkamp, C. R., Seshadri, S., Holewinski, R. J., Andrésson, Þ., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.004 · Cited by 44
Small molecular inhibitors for KRAS-mutant cancers
Wu, X., Song, W., Cheng, C., Liu, Z., Li, X., Cui, Y., Gao, Y., & Li, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223433 · Cited by 47
“Attempts to develop effective agents that inhibit RAS mutations have been a failure for a long time (7, 8).”
BackgroundG-quadruplexes in cancer-related gene promoters: from identification to therapeutic targeting
Romano, F., Porzio, A. D., Iaccarino, N., Riccardi, G., Lorenzo, R. D., Laneri, S., Pagano, B., Amato, J., & Randazzo, A. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2271168 · Cited by 47
“The oncogenes HRAS and NRAS are the other members of the RAS gene family, and mutations in these genes are commonly observed in various human cancers [129–131].”
BackgroundNiida, A., Sasaki, S., Yonemori, K., Sameshima, T., Yaguchi, M., Asami, T., Sakamoto, K., & Kamaura, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.063 · Cited by 42
Novotny, C. J., Hamilton, G. L., McCormick, F., & Shokat, K. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00374 · Cited by 41
Murillo, M. M., Rana, S., Spencer-Dene, B., Nye, E., Stamp, G., & Downward, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.003 · Cited by 39
“RAS is critical for the activation of the RAF pathway and also contributes directly to activation of the PI3K pathway through direct binding of RAS proteins to a RAS-binding domain (RBD) in the PI3K p110 catalytic subunit (Cox et al., 2014; Fritsch et al., 2013; RodriguezViciana et al., 1994).”
KRAS: A Promising Therapeutic Target for Cancer Treatment
Wu, H.-Z., Xiao, J., Xiao, S., & Cheng, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190905164144 · Cited by 43
Telford, B. J., Yahyanejad, S., de Gunst, T., den Boer, H. C., Vos, R. M., Stegink, M., van den Bosch, M. T. J., Alemdehy, M. F., van Pinxteren, L. A. H., Schaapveld, R. Q. J., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27894 · Cited by 44
“Expression of oncogenic KRAS is linked to aggressive disease and therapeutic resistance, yet despite years of effort no effective inhibitor has reached the clinic [35, 36].”
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 47
Rahman, Z., Bazaz, M. R., Devabattula, G., Khan, M. A., & Godugu, C. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22674 · Cited by 45
Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice
Tolani, B., Celli, A., Yao, Y., Tan, Y. Z., Fetter, R. D., Liem, C. R., de Smith, A. J., Vasanthakumar, T., Bisignano, P., Cotton, A. D., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01386-z · Cited by 48
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Federico, A. D., Ricciotti, I., Favorito, V., Michelina, S. V., Scaparone, P., Metro, G., Giglio, A. D., Pecci, F., Lamberti, G., Ambrogio, C., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01436-y · Cited by 47
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
Serini, S., & Calviello, G. (2017) · Nutrients · doi:10.3390/nu9030185 · Cited by 43
“Whereas direct RAS targeting has not allowed us to obtain a drug suitable for human use [23], in recent years a series of RAF and MEK specific inhibitors has been developed against several kinds of Ras/Raf/MEK/ERK-driven cancers [23].”
BackgroundAkao, Y., Kumazaki, M., Shinohara, H., Sugito, N., Kuranaga, Y., Tsujino, T., Yoshikawa, Y., & Kitade, Y. (2018) · Cancer Science · doi:10.1111/cas.13559 · Cited by 40
“which can be changed to the activated state by extracellular stimuli such as the presence of mitogens, cytokines and growth factors.(6) On activation, Ras exerts its functions through protein-protein interactions with effectors, such as Raf kinase and PI3K, to promote cell growth and survival.”
BackgroundInfluentialRASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis
Schmidt, M., Hobbing, K. R., Donninger, H., & Clark, G. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2466 · Cited by 44
“Activating mutations in the Ras oncogenes, primarily K-ras, are the most common mutations identified in human cancer (2).”
Miller, J. B., & Siegwart, D. J. (2018) · Nano Research · doi:10.1007/s12274-018-2099-4 · Cited by 40
Sasayama, Y., Hasegawa, M., Taguchi, E., Kubota, K., Kuboyama, T., Naoi, T., Yabuuchi, H., Shimai, N., Asano, M., Tokunaga, A., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.004 · Cited by 41
ARF family GTPases with links to cilia
Fisher, S. I., Kuna, D., Caspary, T., Kahn, R., & Sztul, E. S. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2020 · Cited by 42
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth
Vidimar, V., Beilhartz, G. L., Park, M., Biancucci, M., Kieffer, M. B., Gius, D. R., Melnyk, R. A., & Satchell, K. J. F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000312117 · Cited by 44
Dasgupta, A., Sierra, L., Tsang, S. V., Kurenbekova, L., Patel, T. D., Rajapakshe, K., Shuck, R. L., Rainusso, N. C., Landesman, Y., Unger, T. J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0854 · Cited by 40
“This is partly due to the difficulty to directly target RAS, for the lack of deep hydrophobic pockets for binding of small-molecule inhibitors (7).”
BackgroundLing, X., Wu, W., Aljahdali, I. A. M., Liao, J., Santha, S., Fountzilas, C. K., Boland, P. M., & Li, F. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.881 · Cited by 45
Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics
Yu, H. S., Gao, C., Lupyan, D., Wu, Y., Kimura, T., Wu, C., Jacobson, L., Harder, E., Abel, R., & Wang, L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00268 · Cited by 39
Leung, E. L., Luo, L. X., Li, Y., Liu, Z., Li, L. L., Shi, D. F., Xie, Y., Huang, M., Lu, L. L., Duan, F. G., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32222 · Cited by 39
“Yet to date, no targeted therapies have been used effectively against KRAS mutant lung cancer.(10) Knowledge of”
BackgroundMethodTherapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 44
Liquid‒liquid phase separation: roles and implications in future cancer treatment
Liu, Z., Qin, Z., Liu, Y., Xia, X., He, L., Chen, N., Hu, X., & Peng, X. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81521 · Cited by 46
“KRAS mutation is a prevalent genetic alteration observed in pancreatic adenocarcinoma, lung adenocarcinoma, and colorectal cancer (85).”
BackgroundPP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion
Ma, X., Lu, J., Dong, Y., Li, D., Malagón, J. N., & Xu, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.092 · Cited by 40
“However, despite several decades of concentrated effort and breakthroughs, successful therapeutic methods targeting RAS-related cancers remain to be developed (Cox et al., 2014; Ryan et al., 2015; Stephen et al., 2014), largely due to the lack of a systematic understanding of the complex signaling crosstalk within RAS…”
BackgroundChallenges in Ras therapeutics in pancreatic cancer
Choi, M., Bien, H., Mofunanya, A., & Powers, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.015 · Cited by 43
Shimomura, I., Yokoi, A., Kohama, I., Kumazaki, M., Tada, Y., Tatsumi, K., Ochiya, T., & Yamamoto, Y. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.002 · Cited by 49
Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer
Zaballos, M. A., Acuña-Ruíz, A., Morante, M., Crespo, P., & Santisteban, P. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0098 · Cited by 44
Liu, Z., Wang, M., Wang, H., Fang, L., & Gou, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01223 · Cited by 41
Intrinsic GTPase activity of K-RAS monitored by native mass spectrometry
Moghadamchargari, Z., Huddleston, J., Shirzadeh, M., Zheng, X., Clemmer, D. E., M. Raushel, F., Russell, D. H., & Laganowsky, A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00532 · Cited by 38
Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants
Moghadamchargari, Z., Shirzadeh, M., Liu, C., Schrecke, S., Packianathan, C., Russell, D. H., Zhao, M., & Laganowsky, A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022403118 · Cited by 38
New structural and functional insight into the regulation of Ras
Kano, Y., Cook, J. D., Lee, J. E., & Ohh, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.006 · Cited by 38
“However, these drugs were less than successful in human clinical trials[28].”
BackgroundImmunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
Pan, J., Zhang, Q., Sei, S., Shoemaker, R. H., Lubet, R. A., Wang, Y., & You, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19831 · Cited by 38
“RAS genes (HRAS, NRAS and KRAS) are the most frequently mutated oncogene family in human cancers [23], and is strongly associated with cigarette smoking [24].”
BackgroundTargeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Odeniyide, P., Yohe, M. E., Pollard, K., Vaseva, A. V., Calizo, A., Zhang, L., Rodríguez, F. J., Gross, J. M., Allen, A. N., Wan, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02305-x · Cited by 42
“DISCUSSION Efforts in drug development to selectively target RAS have been a major research and discovery focus since the recognition of RAS as oncoproteins in 1982 [46, 47] and subsequent studies that demonstrate that RAS is a driver oncogene in up to 24% of all human cancers [4].”
BackgroundSrisongkram, T., & Weerapreeyakul, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010669 · Cited by 39
“(2) The KRAS protein lacks a deep surface hydrophobic pocket in an active site, which hinders the development of competitive nucleotide inhibitors [9].”
BackgroundExploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors
Akkapeddi, P., Hattori, T., Khan, I. M., Glasser, E., Koide, A., Ketavarapu, G., Whaby, M., Zuberi, M., Teng, K. W., Lefler, J. E., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302485120 · Cited by 40
“Activating, missense mutations of RAS genes ( KRAS , HRAS, and NRAS ) are frequently associated with human cancers and play important roles in oncogenic transformation (1, 2).”
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Batrash, F., Kutmah, M., & Zhang, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00453-8 · Cited by 43
Zhang, J., Lim, S. M., Yu, M. R., Chen, C., Wang, J., Wang, W., Rui, H., Lu, J., Lü, S., Mok, T. S. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0006 · Cited by 42
“…and offers new insights into the critical features that drive preclinical and clinical efficacy for this class of drugs. intRoduction KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutations represent a distinct molecular subtype and are oncogenic drivers in multiple solid tumors (1) .”
BackgroundPhosphorylation weakens but does not inhibit membrane binding and clustering of K-Ras4B
Zhang, S.-Y., Sperlich, B., Li, F.-Y., Al-Ayoubi, S., Chen, H.-X., Zhao, Y.-F., Li, Y.-M., Weise, K., Winter, R., & Chen, Y.-X. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00165 · Cited by 36
Ruicci, K. M., Pinto, N. C., Khan, M. I., Yoo, J., Fung, K., MacNeil, S. D., Mymryk, J. S., Barrett, J. W., & Nichols, A. C. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.07.010 · Cited by 40
Nakagomi, T., Goto, T., Hirotsu, Y., Shikata, D., Yokoyama, Y., Higuchi, R., Otake, S., Amemiya, K., Oyama, T., Mochizuki, H., et al. (2018) · Cancers · doi:10.3390/cancers10120478 · Cited by 38
“that target key KRAS effectors is diminished by compensatory or parallel pathways [9,10].”
BackgroundProtein-Catalyzed Capture Agents
Agnew, H. D., Coppock, M. B., Idso, M. N., Lai, B. T., Liang, J., McCarthy, A., Warren, C. M., & Heath, J. R. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00660 · Cited by 38
A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1
Park, S. W., Nhieu, J., Persaud, S. D., Miller, M. C., Xia, Y., Lin, Y.-W., Lin, Y., Kagechika, H., Mayo, K. H., & Wei, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47354-7 · Cited by 46
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 43
“Of these, KRAS is the most mutated (86% of all RAS-mutant cancers), followed by NRAS (12%), and HRAS (4%) (107).”
BackgroundDey, S., Kwon, J. J., Liu, S., Hodge, G. A., Taleb, S., Zimmers, T. A., Wan, J., & Kota, J. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0594 · Cited by 43
“Over 90% of PDAC cases exhibit driver oncogenic Kras mutations with initiation of precursor, pancreatic intraepithelial neoplasia (PanIN) lesions, which lead to aggressive metastatic PDAC (6).”
BackgroundInfluentialCleary, J. M., Wang, V., Heist, R. S., Kopetz, S., Mitchell, E. P., Zwiebel, J. A., Kapner, K. S., Chen, H. X., Li, S., Gray, R. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0066 · Cited by 39
“Although there has recently been some progress in developing G12C KRAS inhibitors, by and large, efforts to directly target RAS have been unsuccessful (4, 12, 13).”
BackgroundEmerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
Rudolph, J., Settleman, J., & Malek, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0260 · Cited by 37
Design, synthesis and biological evaluation of KRASG12C-PROTACs
Zhang, X., Zhao, T., Sun, M., Li, P., Lai, M., Xie, L., Chen, J., Ding, J., Xie, H., Zhou, J., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117153 · Cited by 41
Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Francisco, A. P., & Paulo, A. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160829145055 · Cited by 37
Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching
Harrison, R. A., Lu, J., Carrasco, M., Hunter, J., Manandhar, A., Gondi, S., Westover, K. D., & Engen, J. R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.017 · Cited by 37
“Recent advances to target specific Ras mutants directly, such as K-Ras G12C with covalent inhibitors, have generated considerable optimism that direct Ras therapy may be possible [6, 32, 33].”
BackgroundKunz, M., & Hölzel, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9657-1 · Cited by 42
Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma
Schofield, H. K., Zeller, J., Espinoza, C. E., Halbrook, C. J., Vecchio, A. D., Magnuson, B., Fabo, T., Daylan, A. E. C., Kovalenko, I., Lee, H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97422 · Cited by 43
“signaling (22) — both important in pancreatic carcinogenesis (23–27) — have similarly been unsuccessful (28).”
BackgroundARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL
Wang, Y., Guan, G., Cheng, W., Jiang, Y., Shan, F., Wu, A., Cheng, P., & Guo, Z. (2018) · BMC Cancer · doi:10.1186/s12885-018-4517-0 · Cited by 36
Wang, K., Baldwin, G. S., Nikfarjam, M., & He, H. Z. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i33.3709 · Cited by 37
Aronchik, I., Dai, Y., Labenski, M., Barnes, C., Jones, T., Qiao, L., Beebe, L., Malek, M., Elis, W., Shi, T., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0554 · Cited by 38
“KRAS mutations, which account for approximately 85% of all RAS mutations in cancer, are found in approximately 98%, 32%, and 52 % frequency in PDAC, lung adenocarcinoma, and colorectal cancer KRAS mutations, respectively (12).”
BackgroundApproaches to inhibiting oncogenic K-Ras
Gorfe, A. A., & Cho, K. (2019) · Small GTPases · doi:10.1080/21541248.2019.1655883 · Cited by 38
“GTPase activity of Ras due to somatic mutations, typically at codons 12, 13 and 61, is associated with 15–20% of all human cancers, and K-Ras mutations account for 85% of all Ras mutations [4,7,8].”
BackgroundSong, Y., Wang, L., Ran, W., Li, G., Xiao, Y., Wang, X., Zhang, L., & Xing, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00096 · Cited by 41
Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators
Qiu, Y., Wang, Y., Chai, Z., Ni, D., Li, X., Pu, J., Chen, J., Zhang, J., Lu, S., Lv, C., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.014 · Cited by 40
New Approaches to Difficult Drug Targets: The Phosphatase Story
Lazo, J. S., McQueeney, K. E., & Sharlow, E. R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217721142 · Cited by 42
“One famous example is Ras, which has been known to be an oncogene for more than 30 years.(10) It is involved in at least one-third of all human cancers, yet there are no clinically approved drugs that directly target the oncogenic forms of Ras.”
BackgroundFang, X., Zhu, N., Zhong, C., Wang, L., Li, J., Weng, S., Hu, H., Dong, C., Li, D., Song, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102123 · Cited by 38
Vasseur, R., Skrypek, N., Duchêne, B., Renaud, F., Martínez‐Maqueda, D., Vincent, A., Porchet, N., SEUNINGEN, I. V., & Jonckheere, N. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.10.014 · Cited by 43
Konda, J. D., Olivero, M., Musiani, D., Lamba, S., & Renzo, M. F. D. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12042 · Cited by 37
“Recently, efforts to develop direct inhibitors of RAS have gathered new momentum (for reviews, see Cox et al., 2014; Ostrem and Shokat, 2016; Singh et al., 2015).”
BackgroundSemaphorin 3C as a Therapeutic Target in Prostate and Other Cancers
Hui, D. H. F., Tam, K. J., Jiao, I. Z. F., & Ong, C. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030774 · Cited by 40
“However, despite continuing efforts, an effective anti-RAS treatment has yet to be discovered, underlining the need for alternate strategies to target this pathway [99,100].”
BackgroundLiu, M., Qin, Y., Hu, Q., Liu, W., Ji, S., Xu, W., Fan, G., Zeng, Y., Zhang, Z., Xu, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.023 · Cited by 37
Drug resistance in targeted cancer therapies with RAF inhibitors
Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 52
Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer
Zhang, D., Zhang, G., Hu, Z., Wu, L. W., Feng, Y., He, S., Zhang, Y., Hu, Z., Yang, L., Tian, T., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1768 · Cited by 39
“DISCUSSION RAS signaling is one of the most studied biological pathways and plays important roles in tumorigenesis and cancer progression (17-21).”
BackgroundInfluentialMüller, M. P., Jeganathan�, S., Heidrich, A., Campos, J., & Goody, R. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-03973-6 · Cited by 38
Gu, M., Gao, Y., & Chang, P. (2021) · Cancers · doi:10.3390/cancers13102429 · Cited by 35
“In PDAC, the Kirsten rat sarcoma virus oncogene homolog (KRAS) gene is broadly mutated [9].”
BackgroundInfluentialRAS Mutations Are Not Created Equal
Hobbs, G. A., & Der, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0406 · Cited by 35
Self-citationBaldelli, E., Bellezza, G., Haura, E. B., Crinó, L., Cress, W. D., Deng, J., Ludovini, V., Sidoni, A., Schabath, M. B., Puma, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5941 · Cited by 35
“Although a number of genomic and proteomic studies have been conducted over the years to elucidate the effect of KRAS mutations on tumor cells [7, 17, 20] in reality, the true nature of the KRAS signaling architecture in vivo within the complex tumor host microenvironment has so far been only marginally explored.”
BackgroundTargeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
Kießling, M. K., Fontecedro, A. C., Samaras, P., Lang, S., Scharl, M. M., Aguzzi, A., Oldrige, D. A., Maris, J. M., & Rogler, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147682 · Cited by 37
Solassol, J., Vendrell, J. A., Märkl, B., Haas, C., Bellosillo, B., Montagut, C. O., Smith, M. R., O’Sullivan, B., D’Haene, N., Mercier, M. L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163444 · Cited by 39
Structure, signaling and the drug discovery of the Ras oncogene protein
Han, C. W., Jeong, M. S., & Jang, S. B. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.7.062 · Cited by 47
“treatment that applies all Ras mutation (40).”
Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS
Abbott, J. R., Patel, P. A., Howes, J. E., Akan, D. T., Kennedy, J. P., Burns, M. C., Browning, C. F., Sun, Q., Rossanese, O. W., Phan, J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00296 · Cited by 39
Self-citationTautermann, C. S., Binder, F., Büttner, F. H., Eickmeier, C., Fiegen, D., Gross, U., Grundl, M. A., Heilker, R., Hobson, S., Hoerer, S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00857 · Cited by 35
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 35
Real-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS
Zhao, Q., Fujimiya, R., Kubo, S., Marshall, C. B., Ikura, M., Shimada, I., & Nishida, N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108074 · Cited by 39
Targeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 45
“downstream pathway branches and other reasons [9], the design of KRAS targeted drugs Figure 1.”
BackgroundTargeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症:英文版 · doi:10.1002/cac2.12377 · Cited by 39
“GTP-bound RAS activates downstream signaling pathways, leading to a spectrum of biological behaviors in cancer [10].”
BackgroundTang, R., Shuldiner, E. G., Kelly, M. R., Murray, C. W., Hebert, J. D., Andrejka, L., Tsai, M. K., Hughes, N. W., Parker, M. I., Cai, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01049-w · Cited by 42
Rao, G., Kim, I.-K., Conforti, F., Liu, J., Zhang, Y.-W., & Giaccone, G. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.013 · Cited by 34
pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins
Prakash, P., Sayyed-Ahmad, A., & Gorfe, A. A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004469 · Cited by 34
“In the subsequent sections we demonstrate the application of the method on membrane–bound K-Ras, a highly sought after anti-cancer drug target [30,66].”
BackgroundMethod
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.